Antiretroviral News and Research RSS Feed - Antiretroviral News and Research

New study reveals ways to reduce HIV rates in Mexico

New study reveals ways to reduce HIV rates in Mexico

To address the HIV epidemic in Mexico is to address it among men who have sex with men (MSM), because they account for a large percentage of the country's new infections, says Omar Galárraga, assistant professor of health services policy and practice in the Brown University School of Public Health. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
Research roundup: Older consumers' spending on health care; hospital leaders' views of reporting quality

Research roundup: Older consumers' spending on health care; hospital leaders' views of reporting quality

In 2011, households with at least one member between ages 50 and 64 spent 8 percent of their total budget on health items, compared with 19 percent for those age 85 or over. [More]
HIV-infected users of stimulants derive benefits from antiretroviral therapy

HIV-infected users of stimulants derive benefits from antiretroviral therapy

New clinical research from UC San Francisco shows that 341 HIV-infected men who reported using stimulants such as methamphetamine or cocaine derived life-saving benefits from being on antiretroviral therapy that were comparable to those of HIV-infected men who do not use stimulants. [More]
Penn Medicine to explore therapeutic strategies for HIV positive women at risk of cervical cancer

Penn Medicine to explore therapeutic strategies for HIV positive women at risk of cervical cancer

The introduction of antiretroviral drugs in Botswana over the last two decades has increased the life expectancies of people living with HIV—many of whom are women co-infected with the human papillomavirus virus (HPV)—considerably: from 39 years to the low 60s. As a result, this co-infected group of women is at a much higher risk of developing HPV-associated cervical cancer. [More]
BIDMC receives $20 million grant to evaluate, test monoclonal antibodies for HIV treatment

BIDMC receives $20 million grant to evaluate, test monoclonal antibodies for HIV treatment

Beth Israel Deaconess Medical Center has received a four-year, $20 million grant from the Bill & Melinda Gates Foundation to evaluate and test broadly neutralizing monoclonal antibodies for the treatment of HIV. [More]
UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

UCSF gets CDC grant to provide expert guidance to clinicians who prescribe anti-HIV medications

The UCSF Clinician Consultation Center at San Francisco General Hospital and Trauma Center has been funded by the Centers for Disease Control and Prevention to provide a PrEPline, a telephone consultation service that gives expert guidance to healthcare providers across the nation who prescribe antiretroviral medications to HIV uninfected individuals to prevent HIV. [More]
New NIH program awards $2.5 million to spur innovation in mobile health

New NIH program awards $2.5 million to spur innovation in mobile health

A new NIH program is awarding nearly $2.5 million to spur innovation in mobile communication technologies and software applications used in biomedical research in low- and middle-income countries (LMICs). [More]
Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen announces availability of PREZCOBIX for Canadians living with HIV

Janssen Inc. announced today that PREZCOBIX (darunavir/cobicistat), a once-daily, oral medication for the treatment of HIV infection in combination with other antiretroviral agents, is now available in Canada. It is the first HIV treatment option available to patients that provides boosted darunavir in a single tablet. [More]
Miriam Hospital receives grant from NIH to prevent spread of sexually transmitted HIV in women

Miriam Hospital receives grant from NIH to prevent spread of sexually transmitted HIV in women

The Miriam Hospital is part of a research collaboration that has received a $20 million grant from the National Institutes of Health (NIH) to develop an intravaginal ring (IVR) that can deliver powerful antiretroviral (ARV) drugs to prevent the spread of sexually transmitted HIV in women. [More]
Mylan releases generic version of Boniva Injection

Mylan releases generic version of Boniva Injection

Mylan Inc. today announced that it has launched Ibandronate Sodium Injection, 1 mg (base)/mL, packaged in 3 mg (base)/3 mL pre-filled glass syringes, which is the generic version of Hoffmann-La Roche's Boniva Injection. [More]

Study: Innovative approaches required to decrease HIV transmission among Russian

Results of a new study conducted in St. Petersburg, Russia, show that decreasing HIV transmission among Russian HIV-infected drinkers will require creative and innovative approaches. [More]
iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics, today reported financial results for the six months ended June 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS"). [More]
FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

FDA accepts Mylan's ANDA filing for generic Copaxone 40 mg/mL

Mylan Inc. today announced that its abbreviated new drug application (ANDA) for a three times per week Glatiramer Acetate Injection 40 mg/mL has been accepted for filing by the U.S. Food and Drug Administration. [More]
FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

FDA approves ViiV Healthcare's Triumeq tablets for treatment of HIV-1 infection

ViiV Healthcare announced today that the US Food and Drug Administration has approved Triumeq (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection. [More]
Mylan launches Potassium Chloride Extended-release Tablets

Mylan launches Potassium Chloride Extended-release Tablets

Mylan Inc. today announced that it has launched Potassium Chloride Extended-release Tablets USP, 8 mEq (600 mg) and 10 mEq (750 mg), which is the generic version of Upsher-Smith's Klor-Con. [More]

Researchers find that same desire for intimacy is strong predictor for PrEp HIV prevention

Men in steady same-sex relationships where both partners are HIV negative will often forgo condoms out of a desire to preserve intimacy, even if they also have sex outside the relationship. [More]
iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs. [More]
Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan Inc. today announced that it has launched Capecitabine Tablets USP, 150 mg and 500 mg, the generic version of Genentech's Xeloda Tablets. Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is indicated as monotherapy, adjuvant therapy and combination therapy for certain types of breast, colon and colorectal cancers. [More]

EGPAF applauds new licensing agreement to improve access to HIV medication for children

The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) applauds the new licensing agreement between the Medicines Patent Pool (MPP) and Gilead Sciences, Inc. to improve access to tenofovir alafenamide fumarate (TAF), a promising new HIV medication. [More]